BioSpace News Archive

Adial Pharmaceuticals, Inc. today announced that William Stilley, Chief Executive Officer and President of Adial Pharmaceuticals, will present at the Dawson James Securities Small Cap Growth Conference being held on October 21, 2021

Encompass Health Corp. (NYSE: EHC) today announced it will participate in the Credit Suisse 30th Annual Virtual Healthcare Conference on November 8, 2021.

Plexision, a biotechnology company, which provides personalized diagnostic testing services for organ transplant patients and for infections that affect immunocompromised patients has received Accreditation by the College of American pathologists for its CLIA-certified reference laboratory in Pittsburgh, PA.

Haichao Wang, PhD, one of The Feinstein Institutes for Medical Research’s leading inflammation and sepsis researchers, has earned the Shock Society’s 2021 Scientific Achievement Award for his years of commitment toward sepsis research and significant contributions to the Society.

The company announces its sixth drug licensed by Bristol Myers Squibb, and the first patients enrolled and dosed in Phase 1 clinical trials evaluating its CC-96191 and CC-92328 NK cell engager therapies in patients with hematologic malignancies.

Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced it will release its third quarter 2021 operating results on Wednesday, November 3, 2021 after market close, with a conference call to follow at 5:30 p.m. Eastern Time.

Athersys, Inc. will release its third quarter 2021 financial results at approximately 4:00 PM Eastern Time on Monday, November 15, 2021, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results.

Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease

NVG-291 Demonstrated to be Well Tolerated Along with a Favorable Pharmacokinetic Profile.

BioMark is proud to participate in this premiere event that aims to address the principal advances in the world of the liquid biopsy.